This is a working overview of HPLC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
The West China School/Hospital of Stomatology (Chinese: 四川大学华西口腔医学院 华西口腔医院) is a public tertiary dental school and hospital in Chengdu, Sichuan, China. Owned and operated by the West China Medical Center of Sichuan University, it specializes in dentistry and oral and maxillofacial medicine. The institution traces its origins to the Renji Dental Clinic established in Chengdu in 1907 by Canadian dentist Ashley Woodward Lindsay. The clinic was expanded into a dental hospital in 1912, and in 1917, the dental school of West China Union University was established. Modern histories of dental education identify the West China Union University dental program as the earliest institution of higher dental education in China. The institution is a Grade-III, Class-A specialist hospital and hosts national clinical, research and training programs in oral medicine. In 2020, the National Health Commission entrusted the institution to serve as one of the three National Centers for Stomatology in the country.
=== Macro-TGA === In TGA, the sample is loaded first before the increase of temperature, and the heating rate is low (less than 100 °C min−1). Macro-TGA can use gram-scale samples to investigate the effects of pyrolysis with mass and heat transfer.
=== Pharmacokinetics === Due to the presence of its C17α methyl group, methylestradiol cannot be deactivated by oxidation of the C17β hydroxyl group, resulting in improved metabolic stability and potency relative to estradiol. This is analogous to the case of ethinylestradiol and its C17α ethynyl group.
The delayed time to peak levels (2–3 hours) and long elimination half-life (12 hours) of suvorexant are less than ideal for an insomnia medication as they result in a delayed onset of effect and significant next-day side effects such as daytime sedation. Orexin receptor antagonists with shorter half-lives and faster onsets of action are theoretically more optimal for therapeutic use as sleep aids. The ideal insomnia medication would not have a duration of action extending beyond about 8 hours. Relative to suvorexant, daridorexant has a shorter half-life (8 hours) while lemborexant has a longer half-life (17–55 hours). However, although lemborexant has a longer terminal elimination half-life than suvorexant, it appears to be more rapidly cleared in the earlier phases of elimination. The investigational agents seltorexant and vornorexant, which are still in clinical trials, have comparatively very short half-lives in the range of 1.5 to 3 hours.
=== Web advertising === In November 2018, the 23 original Kwentong Jollibee videos on its YouTube channel reached a total of 64 million views. After nearly two years the total views had risen to 405 million, with 567,000 subscribers, in July 2020.
Sources: en.wikipedia.org
=== CAR T-cell therapy === HLA-G is both an immune checkpoint and a tumor-specific antigen, making it a target for the development of CAR T-cell therapies, which have been shown to have efficacy in in vitro mouse models. The company Invectys developed the CAR T-cell therapy IVS-3001 targeting HLA-G and began Phase1\2a clinical trials June 2023. Based on preliminary results, IVS-3001 was granted FDA fast track designation, expediting development and review of the therapy for potential use in patients with renal cell carcinoma (RCC).
== History == The first compound of the homolog row of nitriles, the nitrile of formic acid, hydrogen cyanide was first synthesized by C. W. Scheele in 1782. In 1811 J. L. Gay-Lussac was able to prepare the very toxic and volatile pure acid. Around 1832 benzonitrile, the nitrile of benzoic acid, was prepared by Friedrich Wöhler and Justus von Liebig, but due to minimal yield of the synthesis neither physical nor chemical properties were determined nor a structure suggested. In 1834 Théophile-Jules Pelouze synthesized propionitrile, suggesting it to be an ether of propionic alcohol and hydrocyanic acid. The synthesis of benzonitrile by Hermann Fehling in 1844 by heating ammonium benzoate was the first method yielding enough of the substance for chemical research. Fehling determined the structure by comparing his results to the already known synthesis of hydrogen cyanide by heating ammonium formate. He coined the name "nitrile" for the newfound substance, which became the name for this group of compounds. In 1903, Arthur Lapworth investigated the formation of cyanohydrins by addition of hydrocyanic acid to aldehydes and ketones and discovered that the actual nucleophile is the cyanide ion, such that the addition of a base increases the reaction rate. This work represented one of the earliest investigations of an organic reaction mechanism. For a long time, nitriles were primarily of academic interest. Between the First and Second World War, however, research activity increased significantly.
== Justification == Topical drug delivery is a route of administering drugs via the skin with the intent to provide therapeutic effects. This system usually provides a local effect on certain organs. In ancient times, people used herbs on wounds for relieving the inflammatory effect or as pain relievers. There are numerous dosage forms that can be used topically, including cream, ointment, lotion, patches, and other forms. The topical use has many advantages: avoiding first pass metabolism which can increase its bioavailability, being convenient and easy to apply to a large area, being easy to terminate the medication, and avoiding gastrointestinal irritations. All these can increase patient compliance. However, there are several disadvantages to this system – causing skin irritations and symptoms like rashes and itchiness may occur. Also, only small particles can pass through the skin, which limits the choice of drugs. Since skin is the main medium of the topical drug delivery system, its conditions determine the rate of skin penetration leading to affecting the pharmacokinetics of the drug. The temperature, pH value, and dryness of the skin need to be considered. There are some novel topical drugs in the market which can utilise the system as much as possible. This localized system provides topical therapeutic effects via skin, eyes, nose, and vagina to treat diseases. The most common usage is for local skin infections.
Chronic infections Chemotherapeutic & Cytotoxic drugs 5-fluorouracil Hydroxyurea Hydroxycarbamide Methotrexate Following Granulocyte colony stimulating Factor (G-CSF) administration Steroid therapy for immune thrombocytopenic purpura (ITP) Iron deficiency anaemia
Sources: en.wikipedia.org
== Interactions and contraindications == Grazoprevir is transported by the solute carrier proteins SLCO1B1 and SLCO1B3. Drugs that inhibit this proteins, such as rifampicin, ciclosporin, and a number of HIV medications (atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cobicistat), can cause a significant increase in grazoprevir blood plasma levels. Combination of elbasvir/grazoprevir with these drugs is therefore contraindicated. Both elbasvir and grazoprevir are degraded by the liver enzyme CYP3A4. Combination with drugs that induce this enzyme, such as efavirenz, carbamazepine or St. John's wort, is contraindicated because it can lead to ineffectively low plasma levels of elbasvir and grazoprevir. Combination with CYP3A4 inhibitors may increase plasma levels and is not recommended by the manufacturer.
=== Selected publications === NEJM 2025 – CagriSema Trial Lancet 2024 – Semaglutide HFpEF NEJM 2021 – Semaglutide Obesity Diabetes Care 2018 – Consensus Report Lancet 2017 – Type 2 Diabetes Diabetologia 2012 – Sedentary Time BMJ 2008 - Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial Clinical Science 1993 – Antioxidant Capacity
== ERLIC == ERLIC (electrostatic repulsion interaction chromatography) is a type of HILIC that relies on electrostatic interactions, coined by Alpert in 2008. The ionic stationary phase in ERLIC is chosen to have a similar charge to the analyte(s) so that the analyte is repelled by the stationary phase but also retained by the aqueous layer, allowing for enhanced interaction of the remaining polar, oppositely-charged functional groups of the analyte. Electrostatic effects have an order of magnitude stronger chemical potential than neutral polar effects. These opposing effects can, in some cases, enable isocratic separations, with the mobile phase held constant instead of delivered at a gradient. ERLIC can be used to reduce retention of more polar functional groups and minimize the influence of common ionic groups within a set of analytes.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.